{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:18:20Z","timestamp":1771568300459,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015096","name":"Betta Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.esmoop.2022.100473","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T20:48:14Z","timestamp":1651783694000},"page":"100473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study"],"prefix":"10.1016","volume":"7","author":[{"given":"P.","family":"Xing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2022.100473_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100473_bib2","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: current standards and the promise of the future","volume":"4","author":"Chan","year":"2015","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100473_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/bjc.1986.172","article-title":"Expression of epidermal growth factor receptor (EGF-R) in human lung tumours","volume":"54","author":"Cerny","year":"1986","journal-title":"Br J Cancer"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2022.100473_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0169-5002(00)80233-0","article-title":"Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)","volume":"29","author":"Kris","year":"2000","journal-title":"Lung Cancer"},{"issue":"16","key":"10.1016\/j.esmoop.2022.100473_bib5","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100473_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.esmoop.2022.100473_bib7","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100473_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100473_bib9","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100473_bib10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100473_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40265-020-01441-6","article-title":"Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"81","author":"Mok","year":"2021","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100473_bib12","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100473_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JTO.0b013e3181913c9f","article-title":"EGFR T790M mutation: a double role in lung cancer cell survival?","volume":"4","author":"Suda","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100473_bib14","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100473_bib15","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100473_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100473_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.esmoop.2022.100473_bib18","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100473_bib19","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jtho.2020.09.001","article-title":"Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: a multicenter, open-label, phase 1 trial","volume":"15","author":"Yang","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"16_supplement","key":"10.1016\/j.esmoop.2022.100473_bib20","doi-asserted-by":"crossref","first-page":"CT190","DOI":"10.1158\/1538-7445.AM2020-CT190","article-title":"Abstract CT190: A multicenter, open-label, single-arm, phase II study: the third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)","volume":"80","author":"Lu","year":"2020","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100473_bib21","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jtho.2020.01.010","article-title":"Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation","volume":"15","author":"Shi","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100473_bib22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-2600(20)30455-0","article-title":"Efficacy, safety, and genetic analysis of\u00a0furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study","volume":"9","author":"Shi","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100473_bib23","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jtho.2020.11.028","article-title":"Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC","volume":"16","author":"Nagasaka","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100473_bib24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3747\/co.v18i3.877","article-title":"Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer","volume":"18","author":"Hirsh","year":"2011","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100473_bib25","first-page":"1762","article-title":"Final results from a phase II trial of osimertinib for elderly patients with epidermal growth factor receptor t790m-positive non-small cell lung cancer that progressed during previous treatment","volume":"9","author":"Nakao","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100473_bib26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S2213-2600(19)30267-X","article-title":"Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study","volume":"8","author":"Tan","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100473_bib27","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(19)30504-2","article-title":"Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study","volume":"20","author":"Ahn","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100473_bib28","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jtho.2018.03.025","article-title":"First-in-human phase I study of AC0010, a mutant-selective EGFR inhibitor in non-small cell lung cancer: safety, efficacy, and potential mechanism of resistance","volume":"13","author":"Ma","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100473_bib29","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2022.100473_bib30","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100473_bib31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100473_bib32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/annonc\/mdx820","article-title":"CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials","volume":"29","author":"Goss","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100473_bib33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jtho.2021.10.024","article-title":"Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: updated post-National Medical Products Administration approval results from the APOLLO registrational trial","volume":"17","author":"Lu","year":"2022","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:27:50Z","timestamp":1761856070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922000916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2059702922000916"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100473","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100473"}}